<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124121</url>
  </required_header>
  <id_info>
    <org_study_id>2017-001374-42</org_study_id>
    <nct_id>NCT03124121</nct_id>
  </id_info>
  <brief_title>Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels</brief_title>
  <acronym>GO-LEVEL</acronym>
  <official_title>Study of the Golimumab Exposure-Response Relationship Using Serum Trough Levels</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guy's and St Thomas' NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to gain insight into the exposure-response relationship of&#xD;
      golimumab in moderate-to-severe Ulcerative Colitis (UC).&#xD;
&#xD;
      Patients commencing induction therapy with golimumab will be enrolled into a prospective&#xD;
      study and evaluated at three time-points (weeks 6, 10 and 14) for clinical and biochemical UC&#xD;
      disease activity as well as serum golimumab concentrations and the presence of anti-golimumab&#xD;
      antibodies. Patients already established on stable golimumab maintenance therapy will be&#xD;
      enrolled into a cross-sectional study with the same evaluations taken at a single time point.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will involve two study groups designed to offer insights into the pharmacokinetics&#xD;
      of golimumab during induction and maintenance therapy:&#xD;
&#xD;
      Cohort 1: Patients commencing golimumab induction therapy will be included in a prospective,&#xD;
      observational study.&#xD;
&#xD;
      Cohort 2: Patients receiving golimumab maintenance therapy will be included in a&#xD;
      cross-sectional, observational study.&#xD;
&#xD;
      Primary objective: To define a week 6 serum golimumab concentration that predicts response at&#xD;
      week 14.&#xD;
&#xD;
      Secondary objective: To define serum golimumab concentrations at weeks 6, 10 and 14 that&#xD;
      predict response at each time point, respectively and at week 14.&#xD;
&#xD;
      Exploratory objectives:&#xD;
&#xD;
      Correlations between serum golimumab concentrations and novel disease activity indices&#xD;
      (PRO2), biochemical markers of disease activity (CRP, faecal calprotectin) and quality of&#xD;
      life indices (IBD-Q and IBD-Control).&#xD;
&#xD;
      Correlations between the presence of anti-golimumab antibodies, serum golimumab&#xD;
      concentrations and UC disease activity.&#xD;
&#xD;
      This study will also generate data that can be used to validate a commercially available&#xD;
      golimumab assay as well as a novel patient reported outcome (PRO) assessment of clinical UC&#xD;
      disease activity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 5, 2017</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Golimumab Concentration (μg/ml)</measure>
    <time_frame>Week 6 during induction therapy and at the point of study entry during maintenance</time_frame>
    <description>Evaluated using an enzyme-linked immunosorbent assay (ELISA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients in Clinical Remission</measure>
    <time_frame>Week 14 during induction therapy and at the point of study entry during maintenance therapy</time_frame>
    <description>Evaluated using the Simple Clinical Colitis Activity Index (SCCAI). Remission defined as SCCAI &lt; 3.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Faecal Calprotectin (μg/g)</measure>
    <time_frame>Week 14 during induction therapy and at the point of study entry during maintenance</time_frame>
    <description>Faecal inflammatory marker with higher values suggestive of increasing biochemical disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum C-Reactive Protein (mg/L)</measure>
    <time_frame>Week 14 during induction therapy and at the point of study entry during maintenance</time_frame>
    <description>Serum inflammatory marker with higher values suggestive of increasing biochemical disease activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Albumin (g/L)</measure>
    <time_frame>Week 14 during induction therapy and at the point of study entry during maintenance</time_frame>
    <description>Serum protein marker with higher values associated with increasing inflammatory activity and lower serum levels of anti-TNF agents (such as golimumab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical UC Disease Activity</measure>
    <time_frame>Week 14 during maintenance therapy and at the point of study entry during maintenance</time_frame>
    <description>Evaluated using Patient Reported Outcome 2 (PRO2). PRO2 ranges from 0-5 with higher scores denoting increasing clinical disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (IBD-Control)</measure>
    <time_frame>Week 14 during induction therapy and at the point of study entry during maintenance therapy</time_frame>
    <description>Evaluated using IBD-Control questionnaires. IBD-Control scores range from 0-16 with higher scores denoting better quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With Detectable Anti-golimumab Antibodies</measure>
    <time_frame>At any study time point during induction therapy (weeks 6, 10 or 14) and at the point if study entry during maintenance</time_frame>
    <description>Evaluated using a drug-sensitive enzyme-linked immunosorbent assay (ELISA)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Induction cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Golimumab induction therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Maintenance cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Golimumab maintenance therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Golimumab</intervention_name>
    <description>A biologic agent which acts by antagonising the effects of tumour necrosis factor (TNF) alpha</description>
    <arm_group_label>Induction cohort</arm_group_label>
    <arm_group_label>Maintenance cohort</arm_group_label>
    <other_name>Simponi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for cohort 1:&#xD;
&#xD;
          -  Aged 18 years or over&#xD;
&#xD;
          -  Moderate-to-severe UC, defined as:&#xD;
&#xD;
        SCCAI &gt; 5 and, i. A raised fecal calprotectin (&gt; 59 μg/g) or, ii. A raised CRP (&gt; 5 mg/L)&#xD;
        or, iii. Endoscopic disease activity Mayo 2 or above, Evaluated within 4 weeks of study&#xD;
        enrollment&#xD;
&#xD;
          -  Commencing golimumab treatment&#xD;
&#xD;
          -  Written informed consent to participate&#xD;
&#xD;
          -  Sufficient English language skills to understand the patient information sheet and&#xD;
             consent form&#xD;
&#xD;
        Inclusion Criteria for cohort 2:&#xD;
&#xD;
          -  Aged 18 years or over&#xD;
&#xD;
          -  Receiving golimumab treatment for UC for over 18 weeks (6 injections)&#xD;
&#xD;
          -  Written informed consent to participate&#xD;
&#xD;
          -  Sufficient English language skills to understand the patient information sheet and&#xD;
             consent form&#xD;
&#xD;
        Exclusion Criteria (cohort 1 only):&#xD;
&#xD;
          -  Contra-indication to golimumab: tuberculosis or severe infections&#xD;
&#xD;
          -  Imminent need for colectomy (i.e. colectomy is being planned)&#xD;
&#xD;
          -  Previous primary non-response to anti-TNF therapy in the opinion of the investigator&#xD;
&#xD;
          -  Previous treatment with more than one anti-TNF therapy (excluding golimumab)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Guy's &amp; St Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 21, 2017</study_first_posted>
  <results_first_submitted>May 13, 2021</results_first_submitted>
  <results_first_submitted_qc>June 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 1, 2021</results_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Golimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03124121/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03124121/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Golimumab Induction Therapy</title>
          <description>Patients commencing golimumab</description>
        </group>
        <group group_id="P2">
          <title>Golimumab Maintenance Therapy</title>
          <description>Patients receiving golimumab maintenance therapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39"/>
                <participants group_id="P2" count="67"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Golimumab Induction Therapy</title>
          <description>Patients commencing golimumab</description>
        </group>
        <group group_id="B2">
          <title>Golimumab Maintenance Therapy</title>
          <description>Patients receiving golimumab maintenance therapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="67"/>
            <count group_id="B3" value="106"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37" lower_limit="24" upper_limit="48"/>
                    <measurement group_id="B2" value="36" lower_limit="20" upper_limit="73"/>
                    <measurement group_id="B3" value="36" lower_limit="20" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="39"/>
                    <count group_id="B2" value="67"/>
                    <count group_id="B3" value="106"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="37"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serum Golimumab Concentration (μg/ml)</title>
        <description>Evaluated using an enzyme-linked immunosorbent assay (ELISA)</description>
        <time_frame>Week 6 during induction therapy and at the point of study entry during maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Golimumab Induction Therapy</title>
            <description>Patients commencing golimumab</description>
          </group>
          <group group_id="O2">
            <title>Golimumab Maintenance Therapy</title>
            <description>Patients receiving golimumab maintenance therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Golimumab Concentration (μg/ml)</title>
          <description>Evaluated using an enzyme-linked immunosorbent assay (ELISA)</description>
          <units>ug/ml</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" lower_limit="1.3" upper_limit="8.0"/>
                    <measurement group_id="O2" value="2.4" lower_limit="0.6" upper_limit="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients in Clinical Remission</title>
        <description>Evaluated using the Simple Clinical Colitis Activity Index (SCCAI). Remission defined as SCCAI &lt; 3.</description>
        <time_frame>Week 14 during induction therapy and at the point of study entry during maintenance therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Induction Cohort</title>
            <description>Patients commencing golimumab</description>
          </group>
          <group group_id="O2">
            <title>Maintenance Cohort</title>
            <description>Patients receiving golimumab maintenance therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients in Clinical Remission</title>
          <description>Evaluated using the Simple Clinical Colitis Activity Index (SCCAI). Remission defined as SCCAI &lt; 3.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Faecal Calprotectin (μg/g)</title>
        <description>Faecal inflammatory marker with higher values suggestive of increasing biochemical disease activity</description>
        <time_frame>Week 14 during induction therapy and at the point of study entry during maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Golimumab Induction Therapy</title>
            <description>Patients commencing golimumab</description>
          </group>
          <group group_id="O2">
            <title>Golimumab Maintenance Therapy</title>
            <description>Patients receiving golimumab maintenance therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Faecal Calprotectin (μg/g)</title>
          <description>Faecal inflammatory marker with higher values suggestive of increasing biochemical disease activity</description>
          <units>ug/g</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="5" upper_limit="2000"/>
                    <measurement group_id="O2" value="57" lower_limit="5" upper_limit="1260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum C-Reactive Protein (mg/L)</title>
        <description>Serum inflammatory marker with higher values suggestive of increasing biochemical disease activity</description>
        <time_frame>Week 14 during induction therapy and at the point of study entry during maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Golimumab Induction Therapy</title>
            <description>Patients commencing golimumab</description>
          </group>
          <group group_id="O2">
            <title>Golimumab Maintenance Therapy</title>
            <description>Patients receiving golimumab maintenance therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Serum C-Reactive Protein (mg/L)</title>
          <description>Serum inflammatory marker with higher values suggestive of increasing biochemical disease activity</description>
          <units>mg/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="1" upper_limit="50"/>
                    <measurement group_id="O2" value="1" lower_limit="1" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Albumin (g/L)</title>
        <description>Serum protein marker with higher values associated with increasing inflammatory activity and lower serum levels of anti-TNF agents (such as golimumab)</description>
        <time_frame>Week 14 during induction therapy and at the point of study entry during maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Golimumab Induction Therapy</title>
            <description>Patients commencing golimumab</description>
          </group>
          <group group_id="O2">
            <title>Golimumab Maintenance Therapy</title>
            <description>Patients receiving golimumab maintenance therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Albumin (g/L)</title>
          <description>Serum protein marker with higher values associated with increasing inflammatory activity and lower serum levels of anti-TNF agents (such as golimumab)</description>
          <units>g/L</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="33" upper_limit="52"/>
                    <measurement group_id="O2" value="47" lower_limit="40" upper_limit="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical UC Disease Activity</title>
        <description>Evaluated using Patient Reported Outcome 2 (PRO2). PRO2 ranges from 0-5 with higher scores denoting increasing clinical disease activity.</description>
        <time_frame>Week 14 during maintenance therapy and at the point of study entry during maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Golimumab Induction Therapy</title>
            <description>Patients commencing golimumab</description>
          </group>
          <group group_id="O2">
            <title>Golimumab Maintenance Therapy</title>
            <description>Patients receiving golimumab maintenance therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical UC Disease Activity</title>
          <description>Evaluated using Patient Reported Outcome 2 (PRO2). PRO2 ranges from 0-5 with higher scores denoting increasing clinical disease activity.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="0" upper_limit="5"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (IBD-Control)</title>
        <description>Evaluated using IBD-Control questionnaires. IBD-Control scores range from 0-16 with higher scores denoting better quality of life.</description>
        <time_frame>Week 14 during induction therapy and at the point of study entry during maintenance therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Golimumab Induction Therapy</title>
            <description>Patients commencing golimumab</description>
          </group>
          <group group_id="O2">
            <title>Golimumab Maintenance Therapy</title>
            <description>Patients receiving golimumab maintenance therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (IBD-Control)</title>
          <description>Evaluated using IBD-Control questionnaires. IBD-Control scores range from 0-16 with higher scores denoting better quality of life.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="0" upper_limit="16"/>
                    <measurement group_id="O2" value="14" lower_limit="0" upper_limit="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With Detectable Anti-golimumab Antibodies</title>
        <description>Evaluated using a drug-sensitive enzyme-linked immunosorbent assay (ELISA)</description>
        <time_frame>At any study time point during induction therapy (weeks 6, 10 or 14) and at the point if study entry during maintenance</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Golimumab Induction Therapy</title>
            <description>Patients commencing golimumab</description>
          </group>
          <group group_id="O2">
            <title>Golimumab Maintenance Therapy</title>
            <description>Patients receiving golimumab maintenance therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With Detectable Anti-golimumab Antibodies</title>
          <description>Evaluated using a drug-sensitive enzyme-linked immunosorbent assay (ELISA)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>During the 14 week induction study for patients commencing treatment and at a single time point (the point of recruitment) for patients on maintenance therapy.</time_frame>
      <desc>Only serious adverse events (including all-cause mortality) were recorded. Non-serious adverse events were not recorded.</desc>
      <group_list>
        <group group_id="E1">
          <title>Golimumab Induction Therapy</title>
          <description>Patients commencing golimumab induction</description>
        </group>
        <group group_id="E2">
          <title>Golimumab Maintenance Therapy</title>
          <description>Patients receiving golimumab maintenance therapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="42"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Ulcerative colitis flare requiring admission</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <description>Azathioprine induced pancreatitis</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Facet join injection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="42"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Mark Samaan</name_or_title>
      <organization>Guy's &amp; St Thomas' Hospital</organization>
      <phone>07740637713</phone>
      <email>mark.samaan@gstt.nhs.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

